NYSE Liffe lists Equity Options on Galapagos
(Thomson Reuters ONE) -
Brussels and Mechelen, Belgium, 30 April 2013 - Today NYSE Liffe, the Europe-
based derivatives business of NYSE Euronext (NYX), added options on the shares
of Galapagos (Euronext: GLPG), a clinical stage biotech company focused on
developing novel medicines, to its highly successful range of equity option
classes. The options are available on the Brussels derivatives market of NYSE
Liffe under the ticker GLS.
Vincent Van Dessel, CEO of NYSE Euronext Brussels commented: "We are pleased to
announce the listing of options on Galapagos, a successful Belgian company and a
great example of our leading role in the biotech industry niche. This listing
will further enhance the visibility of the company."
Ade Cordell, Executive Director, Head of Equity Derivatives added: "We are
delighted with the listing of this new option class on our Brussels market.
With the addition of the Galapagos option class to our existing central order
book contracts, we are offering our market participants a highly diversified set
of liquid derivatives for their investment needs.
Onno van de Stolpe, CEO of Galapagos, commented: "Listing of ordinary shares on
NYSE Euronext has played an important role in the growth of Galapagos since the
IPO in 2005. The listing of options on the shares of our company marks a
further step in the company's development. We believe that this may offer
shareholders an alternative financial instrument on the NYSE Liffe market,
enhance the liquidity of our share, and increase the visibility of Galapagos in
the financial markets."
These American-style options will expire on the third Friday of the expiry month
and will have initial lifetimes of one to twelve months. Options on Galapagos
are introduced under trading symbol GLS.
Each option represents 100 shares in Galapagos and will be centrally cleared via
LCH.Clearnet SA. Liquidity in the options will be supported by All Options
International B.V.. NYSE Liffe lists stock options (also known as individual
equity options) on more than 200 leading European companies via the Amsterdam,
Brussels, London and Paris central order books.
The introduction of the new option class on Galapagos is the second one on a
Belgian biotech company. Galapagos is specialized in novel modes-of-action
medicines, with a large pipeline of four clinical, seven pre-clinical, and 30
discovery small-molecule and antibody programs in cystic fibrosis, inflammation,
antibiotics, metabolic disease, and other indications. The Galapagos Group,
including fee-for-service companies BioFocus, Argenta and Fidelta, has around
800 employees and operates facilities in five countries, with global
headquarters in Mechelen, Belgium.
To mark today's special occasion, Onno van de Stolpe, CEO of Galapagos, rang the
opening bell which denotes the opening of NYSE Euronext's European market,
together with Vincent Van Dessel, CEO of NYSE Euronext Brussels.
About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial markets and
provider of innovative trading technologies. The company's exchanges in Europe
and the United States trade equities, futures, options, fixed-income and
exchange-traded products. With approximately 8,000 listed issues (excluding
European Structured Products), NYSE Euronext's equities markets - the New York
Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca -
represent one-third of the world's equities trading, the most liquidity of any
global exchange group. NYSE Euronext also operates NYSE Liffe, one of the
leading European derivatives businesses and the world's second-largest
derivatives business by value of trading. The company offers comprehensive
commercial technology, connectivity and market data products and services
through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more
information, please visit: http://www.nyx.com.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline of four clinical, seven pre-clinical, and 30 discovery
small-molecule and antibody programs in cystic fibrosis, inflammation,
antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases, about to
enter Phase 2b studies. AbbVie and Galapagos signed a worldwide license
agreement whereby AbbVie will be responsible for further development and
commercialization after Phase 2b. Galapagos has another selective JAK1
inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-
licensed by GlaxoSmithKline in 2012). GLPG0187 is a novel integrin receptor
antagonist currently in a Phase 1b patient study in metastasis. GLPG0974 is the
first inhibitor of FFA2 to be evaluated clinically for the treatment of IBD;
this program is currently in a Proof of Concept Phase 2 study, with results
expected early 2014.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has around 800 employees and operates facilities in five countries,
with global headquarters in Mechelen, Belgium. Further information at:
www.glpg.com
CONTACT
NYSE Euronext
Jean-Yves Daxhelet
Tel.: +32 (0)2 213 13 03
E-mail: jean-yves.daxhelet(at)interelgroup.com
Galapagos
Elizabeth Goodwin, Director Investor Relations
Tel.: +31 6 2291 6240
E-mail: ir(at)glpg.com
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
NYSE Liffe lists Equity Options on Galapagos:
http://hugin.info/133350/R/1697598/559450.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1697598]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Ultra Lithium Completes Second Tranche of Private PlacementDatum: 30.04.2013 - 07:31 Uhr
Sprache: Deutsch
News-ID 254153
Anzahl Zeichen: 8282
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 277 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NYSE Liffe lists Equity Options on Galapagos"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
